2016 Membrane Transport Proteins: Translating Molecules to Medicine Gordon Research Conference and Seminar

2016年戈登膜转运蛋白研究会议题为《将分子转化为药物》 将为临床相关和高度可用药物的研究带来迫切需要的翻译重点 膜转运蛋白。尽管它们占人类基因组的10%，并对 高度流行的疾病(自闭症、糖尿病)以及孤儿和罕见疾病(粘脂症4型，克里斯汀森 膜转运蛋白在很大程度上仍未发挥其作为治疗靶点的潜力。九人组 科学会议是高度跨学科的，汇集了不是 与常规有关：包括干细胞技术、3D有机化合物、化学物质的虚拟开采 宇宙中的抑制剂，以及单分子动力学，作为例子。每次演讲后都有充足的讨论时间， 每天的海报会议和下午的空闲时间为非正式讨论、网络交流提供了大量机会 并形成新的合作关系。一次特别的医药会议将有助于在行业和企业之间建立联盟 学者们应对药物开发管道中的挑战。主旨会议将以GRC为特色 亚历山大·M·克鲁克申克演讲奖获得者，年岩博士，他最近具有里程碑意义的高分辨率结构 人类葡萄糖转运蛋白已经捕捉到了这种膜转运蛋白的挑战和机遇 菲尔德。约150名参与者将来自工业界、学术界、研究机构和 将涵盖所有职业级别，从早期职业调查员(研究生， 博士后研究员)预计将占与会者的50%，从职业生涯中期到高级科学家和 教授们。这一组合为垂直和同行指导以及网络提供了理想的机会，这对 这一领域未来的健康和生产力。第一次，我们将主持一场会议前的研究生 由青年研究人员组织的专门为青年研究人员举办的研究研讨会。GRS将包括海报 会议、简短演讲和由制药、学术界和出版界特邀领导人组成的职业小组， 目标是促进科学和专业发展，并灌输信心和领导技能 学员和研究员。组织者致力于促进妇女的多样性和包容性， 少数群体和残疾人。为此，我们的目标是在演讲者和 讨论领袖，并提高所有代表不足群体的能见度。的另一项创新功能 这个名为《力量一小时》的会议是一个旨在解决女性在科学领域面临的挑战的论坛。至 为了扩大国际影响，与会者选择在美国和美国之间更换会议地点 还有欧洲。最近，会议在佛蒙特州举行，2016年的地点是意大利。GRC 提供种子资金，并直接与会议地点谈判成本，以将费用保持在最低水平。 此申请寻求部分资金，以支付受邀演讲者的注册费用，包括女性和 少数族裔和年轻的调查人员。

The 2016 Gordon Research Conference on Membrane Transporters titled “Translating Molecules to Medicine” will bring an urgently needed translational focus to research on clinically relevant and highly druggable membrane transporters. Although they account for 10% of the human genome and contribute to a gamut of highly prevalent (autism, diabetes) as well as orphan and rare diseases (Mucolipidosis type 4, Christianson syndrome), membrane transporters remain largely untapped in their potential as therapeutic targets. The nine scientific sessions are highly interdisciplinary, bringing together topics and techniques that are not conventionally related: these include stem cell technology, 3D organoids, virtual mining of the chemical universe for inhibitors, and single molecule dynamics, as examples. Ample discussion time after each talk, daily poster sessions and afternoon free time allow plenty of opportunity for informal discussion, networking and forming new collaborations. A special Pharma session will help build consortia between industry and academics to tackle challenges in the drug development pipeline. The Keynote session will feature the GRC Alexander M. Cruickshank Lecture awardee, Dr. Nieng Yan, whose recent landmark high-resolution structures of human glucose transporters have captured the challenges and opportunities of this membrane transporter field. Approximately 150 participants will be drawn from industry, academia, research institutions and government and will span all career levels, ranging from early career investigators (graduate students, postdoctoral fellows) projected to comprise 50% of attendees, to mid-career and senior scientists and professors. This mix offers an ideal opportunity for vertical and peer mentoring, and networking, essential for the future health and productivity of this field. For the first time, we will host a pre-conference Graduate Research Seminar organized by, and exclusively for, young investigators. The GRS will include poster sessions, short talks and a Careers Panel with invited leaders from pharma, academia and publishing sectors, with a goal of fostering scientific and professional development and instilling confidence and leadership skills in student trainees and fellows. The organizers are committed to promote diversity and inclusion of women, minorities and persons of disability. To this end, our goal is to achieve gender parity (50%) in speakers and discussion leaders, and to increase the visibility of all underrepresented groups. Another innovative feature of this conference, the Power Hour, is a forum designed to address challenges that women face in science. To foster international reach, participants have elected to alternate the location of the conference between the US and Europe. Most recently, the conference was held in Vermont, and in 2016 the venue is Italy. The GRC provides seed money and negotiates costs directly with the conference site, to keep expenses at a minimum. This application seeks partial funding to cover registration costs for invited speakers, including women and minorities, and young investigators.